CJC-1295 (with DAC)
CJC-1295 DAC / Drug Affinity Complex CJC-1295
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic GHRH analog that incorporates a maleimidopropionic acid linker enabling covalent binding to serum albumin, extending its half-life to 6-8 days. Developed by ConjuChem Biotechnologies, it produces sustained elevation of growth hormone and IGF-1 levels from a single weekly injection. It is primarily researched for growth hormone deficiency, muscle wasting, and age-related GH decline.
Mecanismo de Acción
Modified GHRH analog conjugated to a Drug Affinity Complex (DAC) that binds serum albumin, dramatically extending half-life. Produces sustained elevation of GH and IGF-1 levels rather than pulsatile release. Continuously stimulates GHRH receptors.
Protocolos de Investigación
Para propósitos de investigación solo. No es asesoramiento médico.
Research protocols use 1-2mg once or twice weekly via subcutaneous injection. The long half-life means GH elevation is sustained, not pulsatile. Less frequent dosing but different pharmacodynamic profile than no-DAC version.
Notas de Investigación
Clinical Research Status
CJC-1295 with DAC reached Phase 2 clinical trials before development was discontinued following a participant death attributed to a myocardial infarction (causality was debated). Published trials demonstrated significant and sustained increases in GH and IGF-1 with weekly or biweekly dosing. The compound remains available through research suppliers despite the halted clinical program.
Key Published Findings
A single 30-60mcg/kg injection produced sustained GH elevation for 6+ days and IGF-1 increases of 1.5-3x baseline lasting up to 2 weeks. The GHRH analog demonstrated dose-proportional pharmacokinetics with predictable IGF-1 responses. Studies showed increases in lean body mass and reductions in visceral fat with repeated administration.
Safety Profile
The sustained GH elevation raises theoretical concerns about prolonged IGF-1 exposure compared to pulsatile protocols. Common side effects include injection site reactions, water retention, paresthesias, and headache. The extended half-life means side effects may persist for days rather than hours, making dose titration more challenging.
Drug Interactions & Contraindications
Same contraindications as the no-DAC variant apply, with additional concern regarding the inability to quickly discontinue effects due to the long half-life. Not recommended in combination with exogenous GH as this may cause excessive IGF-1 elevation. Contraindicated in diabetic patients due to GH's insulin-antagonistic effects at sustained high levels.
Comparison to Related Compounds
The DAC variant provides convenience of weekly dosing but sacrifices the physiological pulsatile GH pattern that the no-DAC version produces. Most researchers now prefer the no-DAC version combined with a GHRP for a more natural GH profile with better safety margins. The sustained elevation from DAC may increase risk of side effects associated with chronic GH excess (joint pain, insulin resistance, fluid retention).
Community Observations
Typically dosed at 1-2mg once or twice weekly via subcutaneous injection. Less popular than the no-DAC variant among experienced users due to concerns about blunted GH pulsatility and potential for desensitization. Some users combine it with GHRPs on non-injection days to maintain pulsatile stimulation alongside the baseline elevation.
Media Vida
~6-8 days
Reconstitución
Bacteriostatic water (BAC)
Almacenamiento
Liofilizado
Refrigerate 2-8C up to 24 months.
Reconstituído
Refrigerate 2-8C. Use within 30 days.
Estado Legal EE.UU.
También Se Conoce Como
Preguntas frecuentes
¿Qué es CJC-1295 (with DAC)?
CJC-1295 with DAC (Drug Affinity Complex) is a long-acting synthetic GHRH analog that incorporates a maleimidopropionic acid linker enabling covalent binding to serum albumin, extending its half-life to 6-8 days. Developed by ConjuChem Biotechnologies, it produces sustained elevation of growth hormone and IGF-1 levels from a single weekly injection. It is primarily researched for growth hormone deficiency, muscle wasting, and age-related GH decline.
¿Cómo funciona CJC-1295 (with DAC)?
Modified GHRH analog conjugated to a Drug Affinity Complex (DAC) that binds serum albumin, dramatically extending half-life. Produces sustained elevation of GH and IGF-1 levels rather than pulsatile release. Continuously stimulates GHRH receptors.
¿Cuál es el estado regulatorio de CJC-1295 (with DAC) en EE. UU.?
Research chemical (not FDA-approved)
¿Cuál es la vida media de CJC-1295 (with DAC)?
~6-8 days
¿Qué otros nombres tiene CJC-1295 (with DAC)?
CJC-1295 DAC, Drug Affinity Complex CJC-1295
Peptide Contacts proporciona resúmenes basados en investigaciones únicamente para fines informativos. No hospedamos, distribuimos ni endosamos la documentación del proveedor. Todos los certificados de análisis, certificados GMP y comunicaciones del proveedor deben solicitarse y verificar directamente por el comprador. Nada en esta plataforma constituye asesoramiento legal, médico o profesional. Los usuarios son únicamente responsables de verificar las credenciales del proveedor y asegurarse de cumplir con todas las leyes locales, estatales y federales aplicables antes de comprar cualquier químico de investigación. El uso de esta plataforma constituye aceptación de toda la responsabilidad personal.
Leer aviso completo